RespireRx Pharmaceuticals — Biotech Showcase 2022
13 slides from RespireRx Pharmaceuticals's conference presentation, Dec 14, 2021
Slide 1: Biotech Showcase 2022 Presentation
RespireRx Pharmaceuticals Inc Oye: ES BIOFECH SHOWCASE 2022 PRESENTATION January 2022
Slide 2: Cautionary Notes: Forward Looking Statements
CAUTIONARY NOTES WNQ RespireRx Pharmaceuticals Inc FORWARD LOOKING STATEMENTS This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21 of the Securities Exchange Act of 1934, as ame
Slide 3: RespireRx is developing breakthrough drugs to modify neurotransmission
* Neurons communicate through a process of neurotransmission in which they release chemical neurotransmitters that bind to specific receptors on adjacent neurons. RespireRx is developing breakthrough drugs to modify neurotransmission and create advanced treatments for disorders with high unmet needs
Slide 4: Directly Acting Agonists/Antagonists and Neuromodulators
Pharmaceuticals Inc Directly Acting Agonists/Antagonists ¢ Act directly at the neurotransmitter binding site to either stimulate (agonist) or interfere (antagonist) with the neurotransmitter receptor. NSare ESE * Cannabinoids, such as A9-THC, are direct agonists on the brain’s endocannabinoid recept
Slide 5: Separate Business Units for Different Platforms
Separate Business Units for Different Platforms HA RespireRx Pharmaceuticals Inc RespireRx Pharmaceuticals. Inc. (OTCQB:RSPI) *EndeavourRx *ResolutionRx Neuromodulators Pharmaceutical Cannabinoids *We are contemplating the reorganization as there are several advantages to separating these platforms
Slide 6: Product Portfolio Summary
Product Portfolio Summary WN RespireRx al ta Inc | EndeavourRx | | ResolutionRx { Neurom - Novel Brain Targeting Dru; Pharmaceutical Cannabinoids AMPAkines (AMPA Receptor Positive Allosteric Modulators) Dronabinol (49-THC) = 3 Successful phase 2A trials for CX1739 and CX717 " Treatment of Obstructiv
Slide 7: RespireRx - Product Development Status
RespireRx - Product Development Status DB RespireRx Pharmaceuticals Inc Preclinical Phase 1 Phase 2 Phase 3 ResolutionRx - Cannabinoids Dronabinol — OSA —— Dronabinol Formulation == EndeavourRx - Neuromodulators AMPAkKines CX717 - ADHD Sp CX1739-Spinal Cord Injury CX1942 —follow-up compound =a GABAk
Slide 8: Intellectual Property
Intellectual Property WN RespireRx al ta Inc | EndeavourRx | | ResolutionRx | AMPAKines Dronabinol (49-THC) = Broad family of patents = License to issued method-of-use patent in the US, UK and Germany for the use of dronabinol for , 2 —_— treating OSA (expires 2025 in U.S.) = Patent longevity: compo
Slide 9: Global Market Opportunities
Global Market Opportunities WN RespireRx | EndeavourRx | AMPAKines SCI (Spinal Cord Injury): = Estimated 288,000 patients in US; $ multi-100 million market ADHD (Attention Deficit Hyperactivity Disorder): = Multi$ billion market, dominated by habit-forming scheduled drugs GABAkines Epilepsy: = § mul
Slide 10: RespireRx - Organizational Structure
RespireRx - Organizational Structure HA Resp ireRx Pharmaceuticals Inc 10
Slide 11: Short-Term Milestones
Short-Term Milestones NQ RespireRx dhe Inc | EndeavourRx | | ResolutionRx | AMPAkines Dronabinol (A9-THC) = PK studies with new formulation Initiate SCI phase 2A studies Patent filings = Patent filings = Pre-IND meeting with FDA GABAKIIE® = Phase 3 design completion = Complete pre-clinical developme
Slide 12: Corporate Summary
Corporate Summary RQ RespireRx See ce Inc v Highly desirable assets — advancing clinical programs and patent estate v Diverse portfolio of novel products across multiple therapeutic categories and indications v Broad flexibility in identifying unique investment structures v Strategic partners afford
Slide 13: RSE
RSE TA CtS. rut OTCQB 6 9) Pharmaceuticals Inc